XETRA Healthcare Biotechnology NP5.DE

Newron Pharmaceuticals S.p.A.

$ 13.25 -1.12 %

Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.

CEO: Stefan Weber - https://www.newron.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ -21.36

Loading data...

NP5.DE vs S&P500

Loading data...

No data available.

Quick ratio

0.76

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

-20.08

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.66

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

277.88 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

-17.05 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

8.16

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

-3.43

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

1.60

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
7 indicates good financial health
Altman score
5.72 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.24 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.95 indicates a moderate level of debt, which is generally acceptable but may present some risk
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.